Breaking: Is Beigene Ltd (ADR) a Buy? The Stock Reaches All-Time High Today

Breaking: Is Beigene Ltd (ADR) a Buy? The Stock Reaches All Time High Today

The stock of Beigene Ltd (ADR) (NASDAQ:BGNE) reached all time high today, Nov, 10 and still has $47.41 target or 32.00% above today’s $35.92 share price. This indicates more upside for the $1.23B company. This technical setup was reported by Barchart.com. If the $47.41 PT is reached, the company will be worth $393.60 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 6.27% or $2.12 during the last trading session, hitting $35.92. About 129,067 shares traded hands or 38.64% up from the average. Beigene Ltd (ADR) (NASDAQ:BGNE) has risen 8.16% since April 8, 2016 and is uptrending. It has outperformed by 2.51% the S&P500.

According to Zacks Investment Research, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.”

More important recent Beigene Ltd (ADR) (NASDAQ:BGNE) news were published by: Marketwatch.com which released: “BeiGene Ltd. ADR” on October 25, 2015, also Quotes.Wsj.com published article titled: “DOW JONES, A NEWS CORP COMPANY”, Businesswire.com published: “Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program” on February 08, 2016. More interesting news about Beigene Ltd (ADR) (NASDAQ:BGNE) was released by: Marketwatch.com and their article: “BeiGene, first IPO of 2016, begins trading above issue price” with publication date: February 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment